- Home
- ROIV vs KBR Comparison
ROIV vs KBR Comparison
Compare ROIV & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- KBR
- Stock Information
- Founded
- ROIV 2014
- KBR 1901
- Country
- ROIV United Kingdom
- KBR United States
- Employees
- ROIV N/A
- KBR N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- KBR Military/Government/Technical
- Sector
- ROIV Health Care
- KBR Industrials
- Exchange
- ROIV Nasdaq
- KBR Nasdaq
- Market Cap
- ROIV 7.8B
- KBR 6.3B
- IPO Year
- ROIV N/A
- KBR 2006
- Fundamental
- Price
- ROIV $11.85
- KBR $49.61
- Analyst Decision
- ROIV Buy
- KBR Buy
- Analyst Count
- ROIV 3
- KBR 8
- Target Price
- ROIV $15.25
- KBR $60.29
- AVG Volume (30 Days)
- ROIV 4.6M
- KBR 1.7M
- Earning Date
- ROIV 08-11-2025
- KBR 07-31-2025
- Dividend Yield
- ROIV N/A
- KBR 1.33%
- EPS Growth
- ROIV N/A
- KBR 86.03
- EPS
- ROIV N/A
- KBR 2.75
- Revenue
- ROIV $23,233,000.00
- KBR $8,047,000,000.00
- Revenue This Year
- ROIV $3.28
- KBR $11.69
- Revenue Next Year
- ROIV $156.84
- KBR $6.58
- P/E Ratio
- ROIV N/A
- KBR $16.39
- Revenue Growth
- ROIV N/A
- KBR 12.31
- 52 Week Low
- ROIV $8.73
- KBR $43.89
- 52 Week High
- ROIV $13.06
- KBR $72.60
- Technical
- Relative Strength Index (RSI)
- ROIV 58.16
- KBR 56.37
- Support Level
- ROIV $10.90
- KBR $48.30
- Resistance Level
- ROIV $12.12
- KBR $50.67
- Average True Range (ATR)
- ROIV 0.30
- KBR 1.29
- MACD
- ROIV 0.03
- KBR 0.32
- Stochastic Oscillator
- ROIV 77.87
- KBR 83.15
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.